PET-CT imaging of lymphoma

Clinical PET-CT in Radiology: Integrated Imaging in Oncology

Volumn , Issue , 2011, Pages 267-293

  Kostakoglu, Lale ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892848665     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48902-5_22     Document Type: Chapter

References (125)

1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. NEJM 1992;327:1478-1484.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. NEJM 1993;328:1002-1006.
3. Marshall WH Jr, Breiman RS, Harell GS, Glatstein E, Kaplan HS. Computed tomography of abdominal para-aortic lymph node disease: preliminary observation with a 6 second scanner. Am J Roentgenol 1977;128:759-764.
4. Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. MAGMA 1996;4:213-224.
5. Nyman R, Forsgren G, Glimelius B. Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging. Acta Radiol 1996;37:323-326.
6. Front D, Bar-Shalom R, Mor M, et al. Hodgkin's disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology 1999;210:487-491.
7. Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000;214:253-257.
8. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995,36:1790-1796.
9. Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999;20:13-20.
10. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-348.
11. Thill R, Neuerburg J, Fabry U, et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 1997;36:234-239.
12. Mainolfi C, Maurea S, Varrella P, Alaia C, Imparato C, Alfano B, Aate G, Bazzicalupo L. Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment. Radiol Med 1998;95:98-104.
13. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055-1063.
14. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-728.
15. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, Reske SN. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-481.
16. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-433.
17. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38:799-804.
18. Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999;34: 545-551.
19. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575-581.
20. Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002;94:879-888.
21. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002;75:S24-30.
22. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49: 2112-2135.
23. Jaffe E, Harris N, Diebold J, Muller-Hermelink H-K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999;111(Suppl 1):S8-S12.
24. Harris N, Jaffe E, Diebold J, et al. The World Health Organization classification of hematological malignancies. Report of the Clinical Advisory Committee Meeting. Mod Pathol 2000;13:193-207.
25. Armitage JO. Treatment of non-Hodgkin's lymphoma. NEJM 1993;328:1023-1030.
26. Orlandi E, Lazzarino M, Brusamolino E, Paulli M, Astori C, Magrini U, Bernasconi C. Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 1997;26:359-368.
27. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswold meeting. J Clin Oncol 1989;7: 1630-1636
28. Rosenberg S. Validity of the Ann Arbor staging system classification from the non-Hodgkin's lymphomas. Cancer Treat Rep 1977;61:1023-1027.
29. Leibenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 1989;7:81-91.
30. Josting A, Diehl V. Current treatment strategies in early stage Hodgkin's disease. Curr Treat Options Oncol 2003;4:297-305.
31. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100: 1989-1996.
32. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003;101:391-398.
33. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology 2004;1:203.
34. Hoane BR, Shields AF, Porter BA, et al. Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging. Am J Hematol 1994;47:100-105.
35. Jung G, Heindel W, von Bergwelt-Baildon M, et al. Abdominal lymphoma staging: is MR imaging with T2-weighted turbo-spinecho sequence: a diagnostic alternative to contrast-enhanced spiral CT? J Comput Assist Tomogr 2000;24:783-787.
36. Ferrucci JT. Advances in abdominal MR imaging. RadioGraphics 1998;18:1569-1586.
37. North LB, Libshitz HI, Lorigan JG. Thoracic lymphoma. Radiol Clin North Am 1990;28:745-762.
38. Tateishi U, Muller NL, Johkoh T, Onishi Y, Arai Y, Satake M, Matsuno Y, Tobinai K. Primary mediastinal lymphoma: characteristic features of the various histological subtypes on CT. J Comput Assist Tomogr 2004;28:782-789.
39. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas-a GELA ("Groupe d'Etude des Lymphomas de l'Adulte") study. Am J Surg Pathol 1996;20:877-888.
40. Lee JKT, Stanley RJ, Sagel SS, et al. Accuracy of computed tomography in detecting intra-abdominal and pelvic adenopathy in lymphoma. Am J Roentgenol 1978;131:675-679.
41. Elstrom R, Guan L, Baker G, et al. Utility of FDG PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-3876.
42. Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001;12:825-830.
43. Hoffmann M, Kletter K, Becherer A, et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64: 336-340.
44. Yeung HW, Young KS, Schoder H, Beal K, Larson SM. Extranodal marginal zone lymphoma (LAT) is frequently positive on FDG PET scan. J Nucl Med 2004;45:93P.
45. Nathwani B, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. J Clin Oncol 1999;17:2486-2492.
46. Ben-Haim S, Bar-Shalom R, Israel O, et al. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1996;14:1936-1942.
47. Shrikanthan S, Zhuang HM, Schuster S, Alavi A. FDG PET imaging in diagnosis of mantle cell lymphoma. J Nucl Med 2004;45:93P.
48. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E. Lymphoma: role of FDG PET in nodal staging. Radiology 1997;203:795-800.
49. Menzel C, Dobert N, Mitrou P, Mose S, Diehl M, Berner U. Positron emission tomography for the staging of Hodgkin's lymphoma. Acta Oncol 2002;41:430-436.
50. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002;81:20-25.
51. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620-625.
52. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2- deoxy-D-glucose positron emission tomography (FDG PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998;9:1117-1122.
53. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, Goerres GW. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004;232:823-829.
54. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000;73:1178-1184.
55. Economopoulos T, Asprou N, Stathakis N, et al. Primary extranodal non-Hodgkin's lymphoma of the head and neck. Oncology 1992;49:484-488.
56. Dodd GD. Lymphoma of the hollow abdominal viscera. Radiol Clin North Am 1990;28:771-783.
57. Yoo CC, Levine MS, Furth EE, Salhany KE, Rubesin SE, Laufer I, Herlinger H. Gastric mucosa-associated lymphoid tissue lymphoma: radiographic findings in six patients. Radiology 1998;208:239-243.
58. Levine MS, Rubesin SE, Pantongrag-Brown L, Buck JL, Herlinger H. Non-Hodgkin's lymphoma of the gastrointestinal tract: radiographic findings. AJR Am J Roentgenol 1997;168(1):165-172.
59. Yuki M, Narabayashi I, Yamamoto K, Shimizu T, Tanaka Y, Tatsumi T, Komori T. Multifocal primary lymphoma of bone: scintigraphy and MR findings before and after treatment. Radiat Med 2000;18:305-310.
60. Lanfermann H, Heindel W, Schaper J, Schroeder R, Hansmann ML, Lehrke R, Ernestus RI, Lackner K. CT and MR imaging in primary cerebral non-Hodgkin's lymphoma. Acta Radiol 1997;38:259-267.
61. Herrlinger U, Schabet M, Clemens M, Kortmann RD, Petersen D, Will BE, Meyermann R, Dichgans J. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 1998;97:257-264.
62. Buhring U, Herrlinger U, Krings T, Thiex R, Weller M, Kuker W. MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393-396.
63. Buckley JA, Fishman EK. CT evaluation of small bowel neoplasms: spectrum of disease. Radiographics 1998;18:379-392.
64. Gospodarowicz MK, Ferry JA, Cavalli F. Unique aspects of primary extranodal lymphomas. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL (eds. ). Non-Hodgkin's lymphomas. Philadelphia: Lippincott Williams & Wilkins, 2004:685-707.
65. Gorg C, Weide R, Schwerk WB. Malignant splenic lymphoma: sonographic patterns, diagnosis and follow-up. Clin Radiol 1997;52:535-540.
66. Rodriguez M, Ahlstrom H, Sundin A, Rehn S, Sundstrom C, Hagberg H, Glimelius B. 18F FDG PET in gastric non-Hodgkin's lymphoma. Acta Oncol 1997;36:577-584.
67. Hoffman JM, Waskin HA, Schifter T, et al. FDG PET in differentiating lymphoma from non-malignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567-575.
68. Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996;7:337-346.
69. Skiest DJ, Erdman W, Chang WE, Oz OK, Ware A, Fleckenstein J. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000;40:274-281.
70. Shipp M, Mauch PM, Harris NL. Non-Hodgkin's lymphomas. In: Devita VT, Hellman S, Rosenberg SA (eds. ). Cancer Principles and Practice of Oncology. Philadelphia: Lippincott, 1997, pp. 2165-2220.
71. Abdel-Dayem HM, Rosen G, El-Zeftawy H, Naddaf S, Kumar M, Atay S, Cacavio A. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Clin Nucl Med 1999;24:319-322.
72. Gundlapalli S, Ojha B, Mountz JM. Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med 2002;27:140-141.
73. Carr R, Barrington SF, Madan B, ÓDoherty MJ, Saunders CA, van der Walt J, Timothy AR. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91: 3340-3346.
74. Moog F, Bangerter M, Kotzerke J, Guhlman A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-609.
75. Rini JN, Manalili EY, Hoffman MA, Karayalcin G, Mehrotra B, Tomas MB, Palestro CJ. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002;27:572-577.
76. Bar-Shalom R, Yefremov N, Haim N, et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology 2003;227:353-360.
77. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262-268.
78. Hong SP, Hahn JS, Lee JD, Bae SW, Youn MJ. 18F-fluorodeoxyglucose- positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan. Yonsei Med J 2003;44:779-786.
79. Sasaki M, Kuwabara Y, Koga H, Clinical impact of whole body FDG PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002;16:337-345.
80. Larson SM, Rasey JS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD, Williams DL. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 1980;64:41-53.
81. Nejmeddine F, Caillat-Vigneron N, Escaig F, Moretti JL, Raphael M, Galle P. Mechanism involved in gallium-67 (Ga-67) uptake by human lymphoid cell lines. Cell Mol Biol (Noisy-le-grand) 1998;44:1215-1220.
82. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology 2003;225-247.
83. Buchmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889-999.
84. Partridge S, Timothy A, ÓDoherty MJ, et al. 2-fluorine-18-fluoro- 2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patients management in a single institution. Ann Oncol 2000;11:1273-1279.
85. Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42:1139-1143.
86. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001;91:302-310.
87. Brandt L, Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncol 2001;40:185-197.
88. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas. Description and validation of prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991;9:211-219.
89. Lewis E, Bernardino ME, Salvador PG, Cabanillas FF, Barnes PA, Thomas JL. Post-therapy CT-detected mass in lymphoma patients: is it viable tissue? J Comput Assist Tomogr 1982;6:792-795.
90. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
91. Hasenclever D, Diehl V. International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. NEJM 1998;339:1506-1514.
92. Rodriguez MA, Fuller LM, Zimmerman SO, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 1993;4:125-131.
93. Theuws JC, Seppenwoolde Y, Kwa SL, Boersma LJ, Damen EM, Baas P, Muller SH, Lebesque JV. Changes in local pulmonary injury up to 48 months after irradiation for lymphoma and breast cancer. Int J Radiat Oncol Biol Phys 2000;47:1201-1208.
94. Cremerius U, Fabry U, Kroll U, Zimny M, Neuerburg J, Osieka R, Bull U. Clinical value of FDG PET for therapy monitoring of malignant lymphoma. Results of a retrospective study in 72 patients. Nuklearmedizin 1999;38:24-30.
95. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood 2001;98:2930-2934.
96. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793-800.
97. Mikhaeel NG, Timothy AR, ÓDoherty MJ, Hain S, Maisey MN. 18-FDG PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma 2000;39:543-553.
98. de Wit M, Bohuslavizki KH, Buchert, Bumann D, Clausen M, Hossfeld DK. 18FDG PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:29-37.
99. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-1184.
100. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14: 123-130.
101. Dittmann H, Sokler M, Kollmannsberger C, et al. Comparison of 18FDG PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 2001;8:1393-1399.
102. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 1994;83:1165-1173.
103. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG after first line chemotherapy in non-Hodgkins lymphoma: is ([18F]FDG PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-419.
104. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. Positron emission tomography predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-1027.
105. Mikhaeel NG, Mainwaring P, Nunan T, Timothy AR. Prognostic value of interim and post treatment FDG PET scanning in Hodgkin lymphoma [abstract]. Ann Oncol 2002;13(Suppl 2):21.
106. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-1363.
107. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. NEJM 1995;333:1540-1545.
108. Cremerius U, Fabry U, Wildberger JE, et al. Pre-transplant positron emission tomography using fluorine-18-fluoro-deoxyglucose predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;30:103-111.
109. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260-267.
110. Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma-rapidly responding patients have more durable remissions. J Clin Oncol 1986;4:160-164.
111. Haw R, Sawka CA, Franssen E, Berinstein HL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol 1994;12:1074-1084.
112. Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, et al. NEJM 1995;20(332):1045-1051.
113. Romer W, Hanauske A-R, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-4471.
114. Kostakoglu L, Coleman M, Somrov S, Leonard JP, Verma S, Sherman CH,. Goldsmith SJ. FDG PET after one cycle of chemotherapy accurately predicts response to therapy in large cell (aggressive) non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). J Nucl Med 2004;45:316P.
115. Hoekstra O, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993;34: 1706-1710.
116. Koss MN. Pulmonary lymphoid disorders. Semin Diagn Pathol 1995;12:158-171.
117. Reddy MP, Graham MM. FDG positron emission tomographic imaging of thoracic Castleman's disease. Clin Nucl Med 2003;28:325-326.
118. Murphy SP, Nathan MA, Karwal MW. FDG PET appearance of pelvic Castleman's disease. J Nucl Med 1997;38:1211-1212.
119. Bragg DG, Chor PJ, Murray KA, et al. Lymphoproliferative disorders of the lung: histopathology, clinical manifestations, and imaging features. Am J Roentgenol 1994;163:273-281.
120. Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000;14:1675-1688.
121. Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J. Falsepositive FDG PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997;38:888-890.
122. Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics 2004;24:1611-1616.
123. Kawano T, Suzuki A, Ishida A, et al. The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy. Eur J Nucl Med Mol Imag 2004;31:31-36.
124. Armitage JO. Bone marrow transplantation. NEJM 1994;330: 827-838.
125. Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, Avril N. Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001;12: 719-722.